Therapeutics

Therapeutic choices beneficial for patients may be available in 1 to 3 years.

Investigators examine the demographic, refractive, PRO data measure.

Patients are serious about procedure and ready to move forward.

Investigators find treatment is an option for treating open-angle glaucoma.

Novel technique provides another option for normal and irregular corneas.

An alternative to drops, the option provides consistent therapeutic levels.

Refractive surgery for treating myopia is linked to low rates of regression, enhancement.

Several hundred genes are associated with congenital forms.

Sublingual troche sedation represents attractive anesthesia option for specific subset of patients with cataracts.

New option may prove to be a solution for cataract cases with unusual corneas.

One surgeon shares the early results of his experience using the new TECNIS Eyhance and TECNIS Eyhance Toric II IOLs in performing the first post-FDA-approved cases in the U.S.

Patients show impressive proptosis and diplopia responses to teprotumumab.

Cataract surgeons must consider medication history as part of preoperative evaluation.

Investigators find options could prove to be alternatives to surgical management.

Phakic lenses are proving to be excellent additions to refractive practices.

Physician pioneers technique offering higher perspective in surgery, outcomes.

With intraoperative sustained release steroids, ophthalmologists can eliminate the gambles of patient adherence.

Study supports preoperative ocular surface optimization with artificial tears.

Change can prove to benefit individuals with diabetes, other comorbidities.

Procedure increases lens stability and improves visual acuity in patients.

Robert Ang, MD, discusses highlights of his AAO 2020 presentation on a study analyzing the vIsual outcomes of a small-aperture IOL implantation in patients with a history of post-laser refractive surgery.

Advances in laser-vision correction provide visual results that often surpass 20/20.

Speaking during the American Academy of Ophthalmology’s virtual 2020 annual meeting, Neal H. Shorstein, MD, explained how physicians at Kaiser Permanente have been using a prophylactic drop-free drug regimen before cataract surgery for more than a decade. Their regimen is so streamlined that the only drop that patients receive in anticipation of cataract surgery is a supplemental dilation drop instilled preoperatively while they are still in the holding area.